More on IPTLD Therapy

Athletic Healthy Man Getting Insulin Therapy

More on Insulin Potentiation Targeted LowDose (IPTLD) Therapy?

Targeted low dose chemotherapy using Insulin as a biologic response modifier is a therapy known as Insulin Potentiation Targeted LowDose therapy (IPTLD). It is an innovative cancer treatment regime that allows for the use of chemotherapy drugs selected according to accepted oncological practice. These drugs are delivered at much lower doses than what is accepted as the standard dose.

The effectiveness of the lower dose is based upon physiologic evidence and clinical experience to be enhanced by using insulin to transport the chemotherapy drugs across the cell membrane into cancer cells. The insulin (which may be considered an off-label use) acts to target the chemotherapy drugs to the cancer cells only. (Note: Off label use of approved drugs is addressed in the Physician’s Desk Reference. It is permissible under FDA law. Insulin has a very long history of safety).

Clinical experience also strongly suggests that this protocol minimizes the side-effects associated with chemotherapy. The most notable impact reported by patients is an improvement in quality of life.

IPTLD practitioners use approximately 1/10th – 1/4th the dose of conventional chemotherapy drugs. Additionally, clinical experience and some studies suggest that the use of insulin as a biological response modifier allows this fractionated dose to yield clinically significant tumor responses.

Note: For more detailed information about how IPTLD works go to

What are the Benefits of IPTLD Therapy?


  • IPTLD more selectively targets cancer cells while affecting relatively few healthy cells.
  • Patients do not suffer the severe side effects of chemotherapy, such as hair loss, fatigue and depression. Thus the patient’s quality of life is significantly improved.
  • Gentle treatment combined with nutritional therapy may sometimes preclude the need for additional surgery or radiation. When surgery or radiation is required, IPTLD may be administered simultaneously.
  • When IPTLD is combined with diet, supplements, immune stimulation and other I.V. therapies, the potential benefits can be multiplied.
  • Patients often report that they are more able and motivated to pursue the work necessary for their own well being by incorporating other cancer-fighting measures such as detoxification, immune-boosting, mind/body exercises, diet modification, exercise and meditation to name a few options.
  • • Treatments require only approximately 1 1/2 hours per appointment and are administered at the Kotsanis Institute on an outpatient basis.

Are There any Side Effects of IPTLD

There may be a few side effects. Some nausea is occasionally experienced for a few hours after the first couple of treatments but this can be easily managed.  Occasionally, white blood cells, red blood cells, and platelets may drop; this is easily managed.

What Types of Cancers Respond to IPTLD

IPTLD treatment has been reported to work well for many different types of cancers. Reports have been noted of the therapy bringing responses and remissions to patients with some very difficult cancers, even in late stages. It is important to note however that each patient is evaluated by type of cancer, the stage of development of the cancer when presented for treatment, and the virulence of the patient’s individual cancer cells in addition to any other pertinent factors.

Will You Cooperate with My Primary Physician and Oncologist During My Treatments?

Prior to being accepted into our Comprehensive Cancer Care Program and beginning IPTLDSM therapy, potential patients must cooperate with an oncologist and a primary physician. Dr. Kotsanis gladly coordinates with a team of physicians. Our Institute is located in Grapevine, Texas – close to the DFW (Dallas Fort Worth) airport. Having been on staff at the Baylor Regional Medical Center in Grapevine, TX – for over 26 years, Dr. Kotsanis has access to almost every kind of specialist.

What Should I Expect When Being Treated?

IPTLD℠ is administered the same way conventional chemotherapy is delivered. The patient sits in a recliner chair as the chemotherapy agent is received through an IV. The treatment may take approximately an hour to an hour and a half.

The numbers of treatments depend upon each patient’s medical profile and how well they respond. The frequency of treatments will also vary with each patient.

What Is The Cost Of IPTLD?

Treatment costs are significantly less than full dose chemotherapy. Costs for nutritional supplements and other complementary treatments will vary based on the type of treatments. Click here to see financial options

Note: The preceding is for educational purposes only and is not meant to suggest any specific treatment nor is it meant to imply that we offer all of these treatments. They should not be considered as generally accepted alternatives to conventional medical treatment. All treatment decisions should be made by the patient in the context of trusted medical advice.


More on Cancer

Research the Kotsanis Institute is Conducting

  • A Quality of Life Study with Patients in the Comprehensive Cancer Care Program and treated with Insulin Potentiation Targeted LowDose Chemotherapy. Sponsored by Best Answer for Cancer Foundation. Oversight by Liberty IRB (Institutional Review Board).

: Defeat Cancer:  15 Doctors of Integrative & Naturopathic Medicine Tell You How by Connie Strasheim
In this book, the author interviewed Dr. Kotsanis as well as many other highly regarded doctors who specialize in cancer treatment.

:  The Kinder, Gentler Cancer Treatment:  Insulin Potentiation Targeted LowDose Therapy by Constantine Kotsanis, Steven Ayre, Hendrieka Fitzpatrick, Thomas Lodi, Frank Shallenberger.


    1. Infection: A Little Known But Potentially Deadly Chemotherapy Side Effect,
    2. The Kinder, Gentler Cancer Treatment, Best Answer for Cancer Foundation, 2009. Constantine A. Kotsanis, MD. = See pages 123-127 for additional web sites, books and articles.
    3. Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Lasalvia-Prisco E, Cucchi S, Vazquez J, Lasalvia-Galante E, Golomar W, Gordon W. Mar;53(3):220-4. Epub 2003 Dec 4. Available at: . Accessed November 10, 2008. , Department of Medicine, School of Medicine, University of Uruguay, Montevideo, Uruguay. Abstract. Research available on request.
    4. Metronomic chemotherapy: Low-dose chemotherapy for advanced cancers. Mayo
    5. Insulin-like Growth Factor Receptor Expression and Function in Human Breast Cancer1. Kevin J. Cullen, Douglas Yee, William S. Sly, James Perdue, Brian Hampton, Marc E. Lippman and Neal Rosen. Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, DC 20007; St. Louis University School of Medicine, St. Louis, Missouri 63104; and the Holland Research Labs, American Red Cross, Rockville, Maryland 20850.[Cancer Research 50, 48-53, January 1, 1990], 1990 American Association for Cancer Research
    6. Liberty Institutional Review Board – The IPTLD Quality of Life Broad Study, Study Design and Protocol,Kotsanis Institute and Best Answer for Cancer Foundation.,
    7. A Few Facts About Cancer,